ArticlebioRxiv : the preprint server for biology2021

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.

Amanda J Griffin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.